MX2018014944A - Tratamiento para la enfermedad de parkinson. - Google Patents
Tratamiento para la enfermedad de parkinson.Info
- Publication number
- MX2018014944A MX2018014944A MX2018014944A MX2018014944A MX2018014944A MX 2018014944 A MX2018014944 A MX 2018014944A MX 2018014944 A MX2018014944 A MX 2018014944A MX 2018014944 A MX2018014944 A MX 2018014944A MX 2018014944 A MX2018014944 A MX 2018014944A
- Authority
- MX
- Mexico
- Prior art keywords
- alkyl
- haloalkyl
- hydrogen
- disease
- parkinson
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La invencion se refiere a un metodo de tratamiento o prevencion de la enfermedad de Parkinson en un sujeto que comprende administrar un compuesto de Formula I en donde, R1 es -NHC(O) C3-6 cicloalquilo y R2 es hidrogeno; o R1 y R2 junto con los atomos de carbono a los que estan unidos forman un anillo aromatico de seis miembros, en donde el anillo esta sustituido con uno o mas grupos seleccionados a partir de hidrogeno y halogeno, alquilo C1-6; R3 y R4 se seleccionan independientemente de entre el grupo que comprende hidrogeno, halogeno, C1-3 alquilo, OC1-3 alquilo, NO2, SC1-3 alquilo, C1-3 haloalquilo, OC1-3 haloalquilo y SC1-3 haloalquilo; o una sal farmaceuticamente aceptable de los mismos.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201621019185 | 2016-06-02 | ||
| IN201621019087 | 2016-06-02 | ||
| PCT/IN2017/050224 WO2017208267A1 (en) | 2016-06-02 | 2017-06-02 | Treatment for parkinson's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018014944A true MX2018014944A (es) | 2019-03-07 |
Family
ID=59388123
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018014944A MX2018014944A (es) | 2016-06-02 | 2017-06-02 | Tratamiento para la enfermedad de parkinson. |
Country Status (25)
| Country | Link |
|---|---|
| US (4) | US10849887B2 (es) |
| EP (2) | EP3463351B1 (es) |
| JP (1) | JP6974357B2 (es) |
| KR (1) | KR102508288B1 (es) |
| CN (1) | CN109475539B (es) |
| AU (1) | AU2017273415B2 (es) |
| BR (1) | BR112018074439A2 (es) |
| CA (1) | CA3024976A1 (es) |
| CL (1) | CL2018003431A1 (es) |
| DK (1) | DK3463351T3 (es) |
| ES (1) | ES2914782T3 (es) |
| HR (1) | HRP20220683T1 (es) |
| HU (1) | HUE059387T2 (es) |
| IL (1) | IL263188B (es) |
| LT (1) | LT3463351T (es) |
| MX (1) | MX2018014944A (es) |
| MY (1) | MY193754A (es) |
| PH (1) | PH12018502457A1 (es) |
| PL (1) | PL3463351T3 (es) |
| PT (1) | PT3463351T (es) |
| RS (1) | RS63243B1 (es) |
| SG (1) | SG11201810294QA (es) |
| SI (1) | SI3463351T1 (es) |
| UA (1) | UA123018C2 (es) |
| WO (1) | WO2017208267A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2911040C (en) | 2012-05-02 | 2021-11-16 | Georgetown University | Treating an .alpha.-synucleinopathy with tyrosine kinase inhibitors |
| RS63243B1 (sr) * | 2016-06-02 | 2022-06-30 | Sun Pharma Advanced Res Co Ltd | Lečenje parkinsonove bolesti |
| CN110606840A (zh) | 2018-06-15 | 2019-12-24 | 日产化学株式会社 | 5-炔基吡啶化合物的制造方法 |
| KR20220024463A (ko) | 2019-06-11 | 2022-03-03 | 썬 파마 어드밴스트 리서치 컴패니 리미티드 | 시뉴클레인병증에 대한 치료 |
| WO2021030783A1 (en) * | 2019-08-15 | 2021-02-18 | Duke University | Compositions and methods for the treatment cancer and cns disorders |
| AU2021317186A1 (en) | 2020-07-31 | 2023-03-16 | Sun Pharma Advanced Research Company Limited | N'-(2-chloro-6-methylbenzoyl)-4-methyl-3-[2-(3-quinolyl)ethynyl]-benzohydrazide for treatment of Alzheimer's Disease |
| WO2023214314A1 (en) | 2022-05-02 | 2023-11-09 | Sun Pharma Advanced Research Company Limited | Vodobatinib for reducing progression of parkinson's disease |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2665709B1 (en) | 2011-01-21 | 2016-12-07 | Sun Pharma Advanced Research Company Limited | Diarylacetylene hydrazide containing tyrosine kinase inhibitors |
| CA2911040C (en) | 2012-05-02 | 2021-11-16 | Georgetown University | Treating an .alpha.-synucleinopathy with tyrosine kinase inhibitors |
| US10150733B2 (en) | 2015-05-18 | 2018-12-11 | Sun Pharma Advanced Research Company Ltd. | Amidoheteroaryl aroyl hydrazide ethynes |
| RS63243B1 (sr) * | 2016-06-02 | 2022-06-30 | Sun Pharma Advanced Res Co Ltd | Lečenje parkinsonove bolesti |
-
2017
- 2017-06-02 RS RS20220497A patent/RS63243B1/sr unknown
- 2017-06-02 CN CN201780044265.3A patent/CN109475539B/zh active Active
- 2017-06-02 CA CA3024976A patent/CA3024976A1/en active Pending
- 2017-06-02 LT LTEPPCT/IN2017/050224T patent/LT3463351T/lt unknown
- 2017-06-02 SI SI201731157T patent/SI3463351T1/sl unknown
- 2017-06-02 MY MYPI2018002187A patent/MY193754A/en unknown
- 2017-06-02 BR BR112018074439-5A patent/BR112018074439A2/pt active Search and Examination
- 2017-06-02 UA UAA201812407A patent/UA123018C2/uk unknown
- 2017-06-02 MX MX2018014944A patent/MX2018014944A/es unknown
- 2017-06-02 WO PCT/IN2017/050224 patent/WO2017208267A1/en unknown
- 2017-06-02 DK DK17743097.2T patent/DK3463351T3/da active
- 2017-06-02 PL PL17743097T patent/PL3463351T3/pl unknown
- 2017-06-02 AU AU2017273415A patent/AU2017273415B2/en active Active
- 2017-06-02 PT PT177430972T patent/PT3463351T/pt unknown
- 2017-06-02 JP JP2018563062A patent/JP6974357B2/ja active Active
- 2017-06-02 HR HRP20220683TT patent/HRP20220683T1/hr unknown
- 2017-06-02 KR KR1020187034626A patent/KR102508288B1/ko active IP Right Grant
- 2017-06-02 US US16/304,914 patent/US10849887B2/en active Active
- 2017-06-02 ES ES17743097T patent/ES2914782T3/es active Active
- 2017-06-02 EP EP17743097.2A patent/EP3463351B1/en active Active
- 2017-06-02 SG SG11201810294QA patent/SG11201810294QA/en unknown
- 2017-06-02 HU HUE17743097A patent/HUE059387T2/hu unknown
- 2017-06-02 EP EP22169420.1A patent/EP4085912A1/en active Pending
-
2018
- 2018-11-21 IL IL263188A patent/IL263188B/en unknown
- 2018-11-22 PH PH12018502457A patent/PH12018502457A1/en unknown
- 2018-11-30 CL CL2018003431A patent/CL2018003431A1/es unknown
-
2020
- 2020-10-01 US US17/061,139 patent/US11583522B2/en active Active
-
2022
- 2022-05-18 US US17/747,472 patent/US11813252B2/en active Active
-
2023
- 2023-10-11 US US18/378,901 patent/US20240066014A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018502457A1 (en) | Treatment for parkinson's disease | |
| PH12021550310A1 (en) | Novel sulfonamideurea compounds | |
| MX2018005890A (es) | Composiciones para tratar atrofia muscular espinal. | |
| PH12016502081A1 (en) | Compounds for treating spinal muscular atrophy | |
| MX2021013075A (es) | Oxisteroles y metodos de uso de los mismos. | |
| MX2018000396A (es) | Compuestos aza sustituidos como inhibidores de cinasa 4 asociada al receptor de interleucina 1 (irak-4). | |
| EA201391486A1 (ru) | Способы и композиции для лечения болезни паркинсона | |
| EA201700077A1 (ru) | Соединения аминопиримидинила в качестве ингибиторов jak | |
| AU2018253590A1 (en) | Imidazopyridazine compounds | |
| EA201790713A1 (ru) | N-АЛКИЛАРИЛ-5-ОКСОАРИЛОКТАГИДРОЦИКЛОПЕНТА[c]ПИРРОЛЬНЫЕ НЕГАТИВНЫЕ АЛОСТЕРИЧЕСКИЕ МОДУЛЯТОРЫ NR2B | |
| MX2019015371A (es) | Derivados de dihidro-pirrolo-piridina. | |
| EA201490269A1 (ru) | Новое производное 1,2,3,4-тетрагидрохинолина, подходящее для лечения диабета | |
| PH12017502009A1 (en) | Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection | |
| EA202192900A1 (ru) | Модуляторы пути интегрированной реакции на стресс | |
| JOP20190233A1 (ar) | نظائر بنزوازيبين بوصفها عوامل مثبطة لتيروزين كيناز بروتون | |
| CY1125082T1 (el) | Υποκατεστημενα τριαζολια και μεθοδοι που σχετιζονται με αυτα | |
| MX2022009736A (es) | Compuestos y metodos de p2x3 y/o p2x2/3. | |
| MX2021006985A (es) | Metodos para el tratamiento de la depresión. | |
| EA201790626A1 (ru) | Макроциклические ингибиторы lrrk2-киназы | |
| MX2017005715A (es) | Potentes moduladores de gamma-secretasa. | |
| EA201590074A1 (ru) | Производное бензодиоксола, способ его получения и его применение | |
| MX2018011592A (es) | Compuesto que tiene actividad inhibitoria de idh mutante, metodo de preparacion y usos del mismo. | |
| PH12020551117A1 (en) | Compositions for preventing or treating uveitis | |
| MX337999B (es) | Derivados de 8-hidroxiquinolina. | |
| PH12018502680A1 (en) | Crystal forms of 9-aminomethyl substituted tetracycline compound and preparation method thereof |